Jose Trevino, M.D.

Pancreatic cancer is a devastating disease.  Current therapies for pancreatic cancer have modest effects as the 5-year overall survival is a discouraging 5-6%.  One contributing factor to increased morbidity and mortality is cancer cachexia. Cachexia is defined as weight loss, muscle atrophy, fatigue, and weakness, in someone who is not actively trying to lose weight.  Cachexia is a devastating condition affecting most cancer patients, but significantly more pronounced in patients with pancreatic cancer and is a significant therapeutic and personal dilemma.  I have a significant background in clinical oncology with specialization in pancreatic cancer.  The aims of my therapies are to improve and extend my patient’s quality of life.  Unfortunately, our therapies can be premature or delayed primarily by the overall health of my patients.  Premature in that we treat weak and malnourished patients that should not be given aggressive therapies for the risk of causing more harm than good.  Delayed in that the patient is too weak and malnourished to receive any therapy and therefore will succumb earlier to their disease.  With the expertise and passion of our collaborative group, we will investigate the possible biologic factors that contribute to pancreatic cancer cachexia.  Our plan will be the future development of strategies to interfere with its deleterious effects on our patient population.  In summary, we hope to improve the quantity of quality life in patients with pancreatic cancer.


Location: University of Florida Health Cancer Center - Florida
Proposal: The Role of Cachexia in Pancreatic Cancer
Mailing List Mailing List
Close Mailing List